News
Shares of Hims & Hers Health skyrocketed to 40% in the premarket following the telehealth company’s partnership announcement ...
Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Hims & Hers ( HIMS) stock popped more than 20% in trading early Tuesday after Novo Nordisk ( NVO) announced a partnership with it and other telehealth platforms to offer patients access to the ...
Novo Nordisk collaborates with telehealth companies to expand sales and access to its weight-loss drug Wegovy, amidst efforts ...
Shares of WW International (NASDAQ:WW), jumped on Tuesday after the firm, formerly called WeightWatchers, partnered with Eli ...
Telehealth company Hims & Hers (HIMS) announced Tuesday that it will begin selling Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy.
Hims and Hers Health Inc. soared in pre-market trading after Novo Nordisk A/S said it would sell its popular weight-loss drug ...
Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...
In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week ...
Hims & Hers stock surges after Novo Nordisk announces Wegovy will be offered through telehealth platforms as shortages ease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results